291: The Fool's Game That Became Standard Practice: Perfusion, the ATF, and What Changed with John Bonham-Carter - Part 1

Biotech loves talk of disruptive technology, but few have repeatedly shifted the industry's direction. This episode of the Smart Biotech Scientist Podcast focuses on an idea once dismissed as a fool's game: process intensification through perfusion—now the backbone of leading biomanufacturing platforms.
Meet John Bonham-Carter, a serial entrepreneur whose fingerprints are on some of biotech's most transformative tools. From putting the once-ignored ATF system and perfusion on the global stage to pushing intensified cell therapy bioprocessing with ERBI, John's story isn't about chasing the next big exit. Instead, it's about spotting unmet needs and building and selling biotools companies more than once.
Topics discussed:
• The story behind the ATF system, and how John Bonham-Carter and his collaborators convinced a conservative industry to adopt perfusion (04:43)
• Early career influences, including family ties to bioprocess equipment manufacturing (05:03)
• Reflections on the biotech industry’s culture of collaboration and the dual motivation to deliver medicines and achieve commercial success (07:18)
• Realities of scaling a startup, trading income for equity, and the role of persistence in sales (09:34)
• Lessons learned from global travel and building professional networks in biotech (10:16)
• The importance of recognizing what drives different biotech companies to adopt new technology (12:25)
• The transition from ATF to co-founding Erbi, a bioprocessing startup focused on small-volume cell therapy (19:05)
• Strategic acquisitions: experiences of being acquired by Repligen and Merck Millipore (22:50)
• Advice for founders on whether to build a company for exit or long-term operation (23:07)
• The limits of leading with technology, and why customer understanding is critical to success (26:10)
Smart insight: For founders, John Bonham-Carter offers practical guidance anchored in self-awareness. Should you build a company for the long haul or for acquisition? The answer: “There isn’t really a right answer...it is, what is the life you want to lead?” Some entrepreneurs thrive at the scale of ten-person teams and relish the handoff to a strategic acquirer. Others yearn to build and steer a 200-person enterprise. Regardless, serving customers and employees well, and being attuned to the market’s shifting demands, matter most. Exit opportunities arise from building value and strategic fit—not from fixating on selling out.
Some ideas are ahead of their time; a few people make a career of being early. This is part bioprocess history, part founder's playbook: why the best technology doesn't automatically win, how to move a conservative industry, and when to sell rather than scale. To go further on both the technology and the business behind it:
• Episodes 191 - 192: Process Intensification Secrets: A Process Engineer's Decision Framework with Andreas Castan
• Episodes 183 - 184: From Lab to Market: Secrets to Commercializing Cutting-Edge Biotech Innovations with Chervee Ho
• Episodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome
• Episodes 165 - 166: Why Your Funding Pitches Fail Despite Brilliant Science (And How to Fix It)
Connect with John Bonham-Carter:
Website: stellion-biosystems.com
LinkedIn: linkedin.com/in/johnbc
Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here (smartbiotechscientist.com/#cmc)
Support the show (buzzsprout.com/2263581/support)